Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2374-4677
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers ; volume:8 ; number:1 ; day:7 ; month:11 ; year:2022 ; pages:1-11 ; date:12.2022
npj Breast cancer ; 8, Heft 1 (7.11.2022), 1-11, 12.2022
- Urheber
-
Qing, Tao
Karn, Thomas
Rozenblit, Mariya
Foldi, Julia
Marczyk, Michal
Shan, Naing Lin
Blenman, Kim
Holtrich, Uwe
Kalinsky, Kevin
Meric-Bernstam, Funda
Pusztai, Lajos
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41523-022-00492-0
- URN
-
urn:nbn:de:101:1-2023012110531296466842
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Qing, Tao
- Karn, Thomas
- Rozenblit, Mariya
- Foldi, Julia
- Marczyk, Michal
- Shan, Naing Lin
- Blenman, Kim
- Holtrich, Uwe
- Kalinsky, Kevin
- Meric-Bernstam, Funda
- Pusztai, Lajos
- SpringerLink (Online service)
Ähnliche Objekte (12)
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Downregulation of EphA2 stability by RNF5 limits its tumor-suppressive function in HER2-negative breast cancers
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Downregulation of EphA2 stability by RNF5 limits its tumor-suppressive function in HER2-negative breast cancers
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Downregulation of EphA2 stability by RNF5 limits its tumor-suppressive function in HER2-negative breast cancers
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow